OBPM looks bullish after this news: "Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico". From a technical point of view there is a double bottom, bullish divergence, small degree downtrend broken and increase in volume.